Effects of folinic acid on forearm blood flow in patients with end-stage renal disease

Nephrology Dialysis Transplantation

Volumn 21, Issue 7, 2006, Pages 1927-1933

  Anderson, Todd J ^a,d   Sun, Yiu Hui ^a   Hubacek, Jaroslav ^a   Hyndman, M Eric ^a   Verma, Subodh ^b   Shewchuk, Lana ^a   Scott Douglas, Nairne ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

Author keywords

Atherosclerosis; Dialysis; Endothelium; Folates; Renal disease

Indexed keywords

ACETYLCHOLINE; ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DIAVITE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINAMIDE; NITROPRUSSIDE SODIUM; PANTOTHENIC ACID; PLACEBO; PYRIDOXINE; RIBOFLAVIN; THIAMINE;

ADULT; ARM BLOOD FLOW; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; AGED; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; FEMALE; FOLIC ACID; FOREARM; HUMANS; KIDNEY FAILURE, CHRONIC; LEUCOVORIN; MALE; MIDDLE AGED; NITROPRUSSIDE; PLACEBOS; REGIONAL BLOOD FLOW; TIME FACTORS; VITAMIN B COMPLEX;

EID: 33745612060     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl083     Document Type: Article

References (20)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169
2. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20
3. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002; 16: 391-399
4. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575
5. Wrone EM, Hornberger JM, Zehnder JL et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426
6. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22: 6-13
7. Thambyrajah J, Landray MJ, McGlynn FJ et al. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000; 102: 871-875
8. Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002; 282: H2167-H2172
9. Buccianti G, Raselli S, Baragetti I et al. 5-Methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002; 17: 857-864
10. van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997; 12 [Suppl 2]: 14-18
11. van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 2002; 45: 1004-1010
12. Verhaar MC, Wever RMF, Kastelein JJP et al. 5-Methyltetrahydrofolate, the active form of folic acid restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97: 237-241
13. Doshi SN, McDowell IF, Moat SJ et al. Folate improves endothelial function in coronary artery disease: An effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001; 21: 1196-1202
14. Doshi SN, McDowell IFW, Moat SJ et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002; 105: 22-26
15. Stroes ES, van Faassen EE, Yo M et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-1134
16. Chan NN, Chan WB, Chan JC. Reduction of total homocysteine levels by oral folic acid fails to improve endothelial function in children with chronic renal failure. Circulation 2003; 107: E6-e7
17. van Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-112
18. Touam M, Zingraff J, Jungers P et al. Effective correction of hyperhomocyteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999; 56: 2292-2296
19. Gonin JM. Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens 2005; 14: 277-281
20. Griffith TM, Chaytor AT, Bakker LM, Edwards DH. 5-Methyltetrahydrofolate and tetrahydrobiopterin can modulate electrotonically mediated endothelium-dependent vascular relaxation. Proc Natl Acad Sci USA 2005; 102: 7008-7013